Loss‐of‐function polymorphisms in NQO1 are not associated with the development of subacute myelo‐optico‐neuropathy
Molecular Genetics & Genomic Medicine · 2024-06 · 12 (6)
DOI: 10.1002/mgg3.2470 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Genetics & Genomic Medicine, online erschienen am 11.06.2024. Verfasst von Hideki Matsumoto und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Gifu University Graduate School of Medicine, Gifu University, Gifu, Japan. Hauptthemen laut MEDLINE: NAD(P)H Dehydrogenase (Quinone), Polymorphism, Single Nucleotide. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Health and Labour Sciences Research Grant for Research on Intractable Diseases from The Ministry of Health, Labour and Welfare, Japan.
Abstract (Originalsprache)
Background
Subacute myelo‐optico‐neuropathy (SMON) is a neurological disorder associated with the administration of clioquinol, particularly at very high doses. Although clioquinol has been used worldwide, there was an outbreak of SMON in the 1950s–1970s in which the majority of cases were in Japan, prompting speculation that the unique genetic background of the Japanese population may have contributed to the development of SMON. Recently, a possible association between loss‐of‐function polymorphisms in NQO1 and the development of SMON has been reported. In this study, we analyzed the relationship between NQO1 polymorphisms and SMON in Japan.
Methods
We analyzed 125 Japanese patients with SMON. NQO1 loss‐of‐function polymorphisms (rs1800566, rs10517, rs689452, and rs689456) were evaluated. The allele frequency distribution of each polymorphism was compared between the patients and the healthy Japanese individuals (Human Genomic Variation Database and Integrative Japanese Genome Variation Database), as well as our in‐house healthy controls.
Results
The frequencies of the loss‐of‐function NQO1 alleles in patients with SMON and the normal control group did not differ significantly.
Conclusion
We conclude that known NQO1 polymorphisms are not associated with the development of SMON.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Gifu University Graduate School of Medicine, Gifu University, Gifu, Japan.
- Clinical Genetics Center, Gifu University Hospital, Gifu, Japan.
- Radioisotope Center, Kyoto Prefectural University of Medicine, Kyoto, Japan.
- Department of Neurology, NHO Suzuka National Hospital, Suzuka, Japan.
- Center for one Medicine Innovative Translational Research, Gifu University, Gifu, Japan.
ORCID-Profile: Hideki Matsumoto
Förderung
- Health and Labour Sciences Research Grant for Research on Intractable Diseases from The Ministry of Health, Labour and Welfare, Japan
Zitieren
APA
Matsumoto, H., Sasai, H., Kawamoto, N., Katsuyama, M., Minamiyama, M., Kuru, S., Fukao, T., Ohnishi, H., & SMON Research Group Members (2024). Loss‐of‐function polymorphisms in NQO1 are not associated with the development of subacute myelo‐optico‐neuropathy. Molecular Genetics & Genomic Medicine, 12(6). https://doi.org/10.1002/mgg3.2470
Vancouver
Matsumoto H, Sasai H, Kawamoto N, Katsuyama M, Minamiyama M, Kuru S, et al. Loss‐of‐function polymorphisms in NQO1 are not associated with the development of subacute myelo‐optico‐neuropathy. Molecular Genetics & Genomic Medicine. 2024;12(6). doi:10.1002/mgg3.2470
BibTeX
@article{Matsumoto2024,
author = {Matsumoto, Hideki and Sasai, Hideo and Kawamoto, Norio and Katsuyama, Masato and Minamiyama, Makoto and Kuru, Satoshi and Fukao, Toshiyuki and Ohnishi, Hidenori and SMON Research Group Members, SMON Research Group Members},
title = {Loss‐of‐function polymorphisms in NQO1 are not associated with the development of subacute myelo‐optico‐neuropathy},
journal = {Molecular Genetics & Genomic Medicine},
year = {2024},
volume = {12},
number = {6},
doi = {10.1002/mgg3.2470}
}
EUVIMED